| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5813338 | Neuropharmacology | 2016 | 12 Pages |
Abstract
Genetic loss of the 5-HT2A receptor compromised the activity of chronic treatment with SSRIs, making this receptor a putative marker to predict ADs response.
Keywords
DcxSNRIsMDEvHPCSSRIs5-bromo-2-deoxyuridineDRNMPFC5-HTTMDDADS5-HTMAF5-HT1A receptor5-HT2A ReceptorBDNFMajor depressive disorderElectrophysiologyBrdU5-HT transporterAntidepressant drugsdoublecortinSerotoninserotonin transporterAntidepressantminor allele frequencyMajor depressive episodemedial prefrontal cortexserotonin norepinephrine reuptake inhibitorSSRIdorsal raphe nucleusHippocampusventral hippocampusPolymorphismSingle nucleotide polymorphismsSNPGenetic
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Gaël Qesseveur, Anne Cécile Petit, Hai Thanh Nguyen, Lionel Dahan, Romain Colle, Samuel Rotenberg, Isabelle Seif, Pauline Robert, Denis David, Jean-Philippe Guilloux, Alain M. Gardier, Céline Verstuyft, Laurent Becquemont, Emmanuelle Corruble,